Investigation of COVID-19 symptoms and potential immunity in the general populatio

Not Applicable

• Conditions: COVID-19 (SARS-CoV-2 infection) symptoms and seroprevalence in the general population; Infections and Infestations

• Registration Number: ISRCTN55886926
• Lead Sponsor: niversity of Cambridge

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-06-01
• Last Update Posted: 20 July 2020
• Study Completion: 2021-06-06

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 90000

Inclusion Criteria

1. Have previously taken part in the INTERVAL, COMPARE or STRIDES studies
2. Have an email address for study participation
3. Reside in mainland England
4. Have a good understanding of the English language, both written and oral (study materials are not tailored to support non-English language speakers)

Exclusion Criteria

1. Have received three invitations from the INTERVAL/COMPARE/ STRIDES research study team to take part in other studies in the past year
2. Have withdrawn their consent to take part in the INTERVAL/COMPARE/STRIDES study

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. Symptoms compatible with COVID-19 measured using online questionnaire information monthly for 12 months<br> 2. Population immunity measured using assay of biomarkers (e.g., IgG antibodies to SARS-CoV-2) on blood samples (obtained at home via finger prick) monthly for 12 months<br>

Secondary Outcome Measures

Name	Time	Method
<br> 1. Asymptomatic or subclinical infections in the population measured using self-reported questionnaire data monthly for 12 months<br> 2. Immunological evidence of previous SARS-CoV-2 infection measured using antibody tests monthly for 12 months<br> 3. Risk factors for subsequent development of any, mild and severe COVID-19 like illnesses (correlates of protection) measured using self-reported monthly questionnaires with concurrent assessment of SARS-Cov-2 specific antibody levels monthly for 12 months<br> 4. Duration of protection from COVID-19 like illness after confirmed infection, measured using SARS-Cov-2 specific antibody levels monthly for 12 months<br>